E. Garrett Ingram is a top biotech executive with intimate expertise of global medicines and market access. She joined Cipla in June 2019 as Chief Commercial Officer and Head of Cipla Therapeutics to lead the transformation of the current and future biotech & specialty platforms. Garrett brings to the role more than twenty years’ experience in pharmaceuticals, biotech, and device marketing. She holds a proven track record of distinguished leadership, guiding organizations successfully through turnarounds, delivering profitability in top and bottom-line growth. In July of 2020, Garrett was appointed President & CEO of Cipla Therapeutics, Inc. leading the institutional specialty business. 2023 Named Top 25 Healthcare technology leader of NJ. Prior to her new role at Cipla, Ms. Ingram served as Chief Marketing Officer at MannKind Corporation, based in California, where she delivered share and net profit growth and led the strategy for new compounds and brand plans for current and future collaborations. In addition, she has served in roles as Senior Vice President, Managed Markets at Dexcom and Vice President, Head of Market Access at Sanofi, where she had responsibility across four of the U.S. Business Units: Diabetes & Cardiovascular, General Medicines, Sanofi Genzyme Specialty Care, and Sanofi Pasteur from 2014 to 2016 leading 7 launches across the organization. Prior to joining Sanofi, she held the position of Vice President of Market Access Strategy at Bristol Myers Squibb (BMS), where she led the access, reimbursement, patient affordability and emerging customer strategy teams across the portfolio of diabetes, RA, cardiovascular, oncology, immunology, neuroscience and pipeline assets. At BMS she was awarded the presidential award for impact by leading the biopharma transformation of the organization post Plavix LOE. Garrett held various leadership roles for six years in the commercial and medical organizations at Novo Nordisk. She served as senior/executive director and AVP of managed markets strategy, pricing and contracting and health economics and outcomes research. In this capacity, Garrett partnered with United Health Group, the Centers for Disease Control (CDC), the YMCA and retail pharmacies to deliver the Diabetes Prevention and Control Alliance (DPCA), an innovative public and private partnership designed to help prevent and control diabetes, pre-diabetes and obesity with evidence-based compliance solutions. She has also served in executive positions within the public and private sectors including extensive marketing, launch, managed care, health economics and multi-product lifecycle experience with Pfizer, Pharmacia/Upjohn, and health care provider organizations. Garrett holds a Bachelor of Science degree from East Carolina University and a master’s degree in public health and community education from the University of South Carolina. She has also completed executive leadership programs in pharmaceuticals and leadership at Wharton School of Business and dedicates her free time to mentorship and making a community impact. Currently she is a board member of Alveus Therapeutics and a board member of Cipla Therapeutics, Inc.